Viking Therapeutics Inc

VKTX

28.440USD

+2.150+8.18%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Viking Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

175 / 392

Overall Ranking

329 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Viking Therapeutics Inc Highlights

StrengthsRisks

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -13.42, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.07M shares, decreasing 20.07% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 16.77K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.13.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

94.059

Target Price

+218.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Viking Therapeutics Inc is 3.80, ranking 392 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

3.80

Change

0



Financials

0.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Viking Therapeutics Inc is 6.94, ranking 198 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.42, which is -32.81% below the recent high of -9.01 and -673.67% above the recent low of -103.80.

Score

Industry at a Glance

Previous score

6.94

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 175/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Viking Therapeutics Inc is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 100.50, with a high of 125.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Viking Therapeutics Inc is 7.02, ranking 118 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 34.37 and the support level at 24.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.64

Change

0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Viking Therapeutics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.53%, representing a quarter-over-quarter decrease of 2.40%. The largest institutional shareholder is The Vanguard, holding a total of 9.96M shares, representing 8.81% of shares outstanding, with 2.44% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

9.97M

-1.61%

Fidelity Management & Research Company LLC

4.93M

-35.34%

State Street Investment Management (US)

4.51M

+19.55%

BlackRock Institutional Trust Company, N.A.

4.41M

+2.44%

Two Sigma Investments, LP

3.64M

+51.36%

JP Morgan Asset Management

2.18M

-13.32%

Susquehanna International Group, LLP

2.10M

+1.59%

Lian (Brian)

1.97M

+1.60%

Morgan Stanley Smith Barney LLC

2.02M

+21.50%

Citadel Advisors LLC

1.90M

+117.46%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Viking Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Viking Therapeutics Inc

VKTX

5.63 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment